Suchergebnisse - "Perrone, Francesco"

PubPharm (20)

1

Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Cascinu, S. | Berardi, R. | Bianco, R. | +22

2

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer : HOBOE phase 3 randomised trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Perrone, F. | De Laurentiis, M. | De Placido, S. | +29

CommentIn: Eur J Cancer. 2019 Sep;118:166-168. - PMID 31374402

3

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3) : a randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2018

von De Placido, S. | Gallo, C. | De Laurentiis, M. | +128

CommentIn: Lancet Oncol. 2018 Apr;19(4):431-432. - PMID 29482984

4

BEVERLY : Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer

enthalten in: Clinical lung cancer | 2016

von Gridelli, C. | Rossi, A. | Ciardiello, F. | +10

5

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer : a systematic review and meta-analysis of individual patient data

enthalten in: The Lancet. Oncology | 2014

von Rossi, A. | Chiodini, P. | Sun, J. | +11

CommentIn: Lancet Oncol. 2014 Oct;15(11):1187-8. - PMID 25232000

6

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7) : a randomised, multicentre, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2014

von Pignata, S. | Scambia, G. | Katsaros, D. | +32

CommentIn: Lancet Oncol. 2014 Apr;15(4):363-4. - PMID 24582485

7

Rationale and design of MILES-3 and MILES-4 studies : two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer

enthalten in: Clinical lung cancer | 2014

von Gridelli, C. | Rossi, A. | Di Maio, M. | +14

8

Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2013

von Lastoria, S. | Piccirillo, M. | Caracò, C. | +13

9

Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2013

von Reaume, M. | Leighl, N. | Mittmann, N. | +11

10

Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations : current evidence and future perspectives

enthalten in: Expert review of anticancer therapy | 2013

von Costanzo, R. | Montanino, A. | Di Maio, M. | +9